JP Morgan sees mixed results in Risk ’s 2002 end-user derivatives rankings

Citigroup, JP Morgan’s main Wall Street adversary, came first in the non-financial companies section, with Royal Bank of Scotland (RBS) coming a close second. Citi was not nearly as popular with asset managers, coming in eighth overall.

2002 End-user rankings table
Non-financial companies
Institution Overall % of vote
Citigroup 15.8
Royal Bank of Scotland 15.6
UBS Warburg 9.8
JP Morgan Chase 8.9
Deutsche Bank 7.8
Asset managers
InstitutionOverall % of vote
JP Morgan Chase17.7
UBS Warburg10.7
Goldman Sachs9.6
Deutsche Bank8.7
Credit Suisse First Boston8.5
Source: Risk

RBS showed clear improvement in this year’s rankings, securing many top positions in sterling and euro products. RBS completed its merger with National Westminster Bank in March 2000 and is focusing on what it calls "joined-up banking" – trying to offer clients the whole range of banking and risk management services. “We like to think we’re a smart debt bank with risk management overlay,” said John McCormick, the bank’s London-based global head of sales and distribution. McCormick served as RBS’s global head of interest rate derivatives until December last year.

Risk surveys major non-financial corporate and asset manager end-users of derivatives globally each year for its rankings. RiskNews' sister publication received 337 detailed responses for this year's survey. Respondents were asked to nominate, in order of preference, their top-three dealers by instrument and currency in the major product classes of over-the-counter interest rate, foreign exchange, equity and credit derivatives.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here